Michelle Bradbury

Associate Professor, Memorial Sloan Kettering Cancer Center

Elucida Oncology, Inc

Michelle S. Bradbury earned a BA in Chemistry from the University of Pennsylvania, an MS in Nuclear Engineering, and a PhD in the Radiological Sciences from the Massachusetts Institute of Technology. This was followed by her formal medical education, which led to board certification in Diagnostic Radiology, a Certificate of Added Qualification (CAQ) in Neuroradiology, and an additional fellowship in Molecular Imaging at MSKCC. She is an currently an Associate Attending Physician and an Associate Member of the Department of Radiology at MSKCC. She holds a Joint Appointment in the Molecular Pharmacology Program at Sloan Kettering Institute, and is an Associate Professor of Radiology at the Gerstner Sloan Kettering Graduate School and Weill Medical College of Cornell University. She is Co-Director of a U54 NCI-awarded MSK-Cornell Center for Translation of Cancer Nanomedicines, as well as the Director of Intraoperative Imaging and Co-Chair of the Innovations and Technology Team at MSK. She has more than 16 years of experience in translational molecular imaging/radiological sciences, coupled with 10 years of applied nanomaterials research. During this time, her work has focused on the co-development and translation of tumor-selective, ultrasmall particle-based imaging tools (C dots) to the clinic for surgical and other medical oncology applications. In the intraoperative setting, fluorescent imaging device co-development has been crucial. For therapeutically-driven studies, dual-modality C dots are being used as drug delivery vehicles to target genetic mutations in brain tumor models. Dr. Bradbury serves as a Principal Investigator of multiple clinical trials involving the C dot platform. A first-in-human clinical trial has already been completed in metastatic melanoma patients using FDA IND approved molecularly-targeted C dot tracer. Additional open clinical trials are intraoperative in nature, either utilizing fluorescent C dots and real-time optical imaging guidance to surgically treat cancer-bearing lymph nodes in melanoma and breast cancer patients or to assess targeted uptake and histologic distributions of the particle tracer in brain tumor patients for therapeutic management. At the other end of the spectrum, nanobiological evaluations, in particular, particle fate studies have addressed endocytotic pathway transport and lysosomal function in a concentration-dependent manner. Recent work has also addressed cell death programs activated in particle-exposed cancer cells. Dr. Bradbury has and continues to serve as a member of several national and international Scientific Advisory Boards in Nanomedicine and Drug Discovery and Development, and is a member of the Nanomedicine Drug Delivery Clinical Trial Working Group at the National Cancer Institute. She is the founding member of Elucida Oncology, Inc., a start-up focused on particle-based clinical trials